

www.jpsr.pharmainfo.in

The impact of IL-10 gene polymorphism on progressive Breast cancer

Azhar Azher Mohammed Al-Ankoshy¹, Ahmed Hamid Dawood Alatbee ²

Jabir ibnHayyan Medical University, Faculty of medicine/Iraq
 Southern technical University, Basra Technical Institute/Iraq

Abstract

Breast cancer is the most frequently diagnosed malignancy and the second leading cause of mortality among women, the cytokine plays a critical role in cancer initiation, progression and elimination as well as the SNPs in IL10 gene -1082 linked with differential levels of IL-10 expression that impact on different type of disease. So the present study deal with correlation of IL-10 polymorphism and progressive of breast cancer.

Case-control study was performed to 70 female patients suffering from breast cancer with group of 70 healthy individual was used as control, the patients at age 35-79 which classified into stages and grade according to TNM classification. Blood sample was collected from all patients and control and used for DNA extracted for using SSP-PCR in detection the IL-10-1082A\G polymorphism.

The result shown that the age range (40-49) were highest than other age range. This result explain a significant association of family history, period of lactation, stage, and grades of cancer with breast cancer. The result demonstrate that AA genotype and A allele is risk factor of severity in breast cancer patients, while GG genotype and G allele is protective factor for severity. Also, the AA genotype had a tow-folded or more increase in T1-2 than GG genotype and 47.5 of patients have +ve results to spread of cancer into lymph node, and founded that the cancer in about 43.4% of patients were metastasis into other organs. However high frequency 54.8% of female patients in grade 3

Conclusion: The polymorphism in IL-10 at position (1082A\G) has association with progression of breast cancer at AA genotype, and IL-10 consider as predictive factor for severity of thalassemia

Key words: Brest cancer, TNM, IL-10 polymorphism

INTRODUCTION

Iraqi National Cancer Research Center (INCRC) considered breast cancer as the commonest type of malignancy in female, affecting one in eight women during their lifetime and the second most common malignancy worldwide and reported about 1,150,000 new cases/year with an incidence of 22 per 100,000 female populations (1). Breast cancer is a complex and multifactorial disease resulting in abnormal cell growth that leads to malignant tumor formation. (2; 3)

Smythet al., (2004) confirmed the role of cytokines in cancer immunity and carcinogenesis (4). Several study illustrated the association of immune-regulatory cytokines like proinflammatory cytokine (IL-6, TNF-a, INF-y) and anti-inflammatory cytokine (IL-10) with several diseases like hepatocellular carcinoma, thalassemia and breast cancer (5, 6 and 7).

Human Interleukin- 10 produced by monocytes, macrophages, Th2 cells and regulatory T cells and act as anti-inflammatory cytokine that regulates the immune response by decreased the production of pro-inflammatory cytokines (8). It has an important coordinated role in breast carcinogenesis (9). IL-10 might promote tumor development, by acting to suppress anti-tumor immune responses (10).

Polymorphic gene sequences in the promoter region of IL-10 gene may influence the gene expression (11) and consequently play a certain role in severity, susceptibility and clinical outcome to several disease by changing cytokine productionsuch as colorectal cancer (12), lung cancer (13), gastric cancer (14), oral cancer(15). So this study aim to focused on correlation between *IL-10* polymorphisms rs1800-896 (-1082 A>G) with breast cancer in Iraqi patients.

PATIENTS AND METHODS

Study population. During period from 1 October 2017 till june 2018, 70 women patients with breast cancer admitted to the Al-Sadder teaching Hospital and oncology unite were prospectively considered. The exclusion criteria were: (a) patient with other type of cancer (b) radiotherapy, or chemotherapy during the previous 3 week; and (c) other active medical conditions (benign breast tumor , heart, hepatic, renal failure, uncontrolled diabetes and infections). In addition to 70 healthy women without history

family of breast cancer admitted to check up breast health were enrolled as control group

The study protocol was approved by the Ethics Committee of ministry of health in Iraq. Informed consent was obtained using a questionnaire completed by each participating subject .

The diagnosis of breast cancer was established by histopathological examination by pathologist .Cancers were staged according to the International Union Against Cancer (IUCC) TNM system (16) .

 $70\,$ blood samples were collected from all female patients and put in EDTA tubes to determination IL10,1082A/G polymorphism. The patients were classified according to . By taken swab from infection area and also after tonsillectomy , the sample surface is sterilized and opened with a sterile scalpel then taken swab from the fibrosis found in the tissue.

Genotyping. Genomic DNA was extracted from EDTA anticoagulant peripheral blood leukocytes using Accupower®Genomic DNA extraction kit (Bioneer. Korea). and then stored at -20 C till use.

Single nucleotide polymorphisms (SNPs) related to the IL-10 (-1082) were determined using PCR with sequence-specific primers (PCR–SSP) in two reactions employing one common forward F:AGCAACACTCCTCGTCGCAACand two reverse primers R1: CCTATCCCTACTTCCCCC and

R2:CCTATCCCTACTTCCCCT (17) , with an amplicon size of 179 bp. The reaction mix was done in 25 μl volumes include $5\mu l$ of template DNA ,GoTaq®Promega Green Master Mix 2X 12.5 μl ,Primers(foreword 2 μl and reverse 2 μl)and Nuclease Free water 3.5 μl (Applied PCR system, USA).

PCR conditions are initial denaturation at 94°C for 5 min, followed by denaturation at 94°C for 30s,annealing at 60°C for 1 min and 1 min of extension at 72°C, with a final extension of 7 min at 72°C., visualized by electrophoresis on a 1% agarose gel stained with 5% ethidium bromide. The gel was then photographed (Cleaver Gel Documentation System) by digital camera on UV light and scored for the presence or absence of an allele specific band

Statistical analysis


Statistical analyses were done using Graf pad prism 5 computer software . To measure the strength of association between 2 categorical variables, such as the presence of certain genotype and

diseasestatus , also differences of genotype and allele frequencies between breast cancer patients and control groups , the odds ratio (OR) and 95% condense intervals (CIs) was assessed by a special $\chi 2$ formula. The difference was considered significant, if p < 0.05.

RESULTS

1-Demography study

The present study show that maximum cases were observed in the age group (40-49) that record 47% while 27% were observed in age range between (50-59) followed by 16% in (60-69) finally 10% (70-79) Fig (1). A result was demonstrated prevalence of patients with family history more than patients without family history Fig(2). Also results explain a significant difference $P \leq 0.05$ in breast feeding and long period of lactation






Figure : distribution of patients according to age (1) and family history (2)

Table(1) The breast feeding and the period in breast cancer women

Breast feeding	
yes	38(54 %)
No	32 (46 %)
Period of breast feeding	38 patients
1-6 month	5(13%)
7-12	7(18%)
1-2 year	10(26%)
More than 2 year	16(43%)

 $(X2 = 7.024 , df = 1 , P value \le 0.05)$

2-disterbution of patients according to Staging and Grading

As show in table (2) the distribution of patients according to size of tumor (T), spread the cancer to lymph node (+ve) or not spread (-ve) as well as if cancer became metastasis (M1) or not (M0). There is a significant difference among different stages ($P \le 0.05$)

The results appear that 14 cases (20%) are grade I, 25 cases (33.7%) are grade II, 31 cases (44.3%) are grade III. There is a significant difference among different grades ($P \le 0.05$) as show in table (2)

Table (2): TNM classification and grading in breast cancer patients

Gategory	Breast cancer No (%)
Tumor stage	
T 1-2	32 (45.7 %)
T 3-4	38 (54.3 %)
Lymph node	
N+ve	40 (57.2 %)
N -ve	30 (42.8 %)
Metastatic	
M0	24 (34.3%)
M1	46 (65.7%)
Grade	
1	14 (20 %)
11	25 (35.7 %)
111	31 (44.3 %)

 $X^2 = 16.060$, df = 3, P value ≤ 0.01)

3- Distribution of IL-10 Gene "-1082 A/G" polymorphism inbreast cancer patients

The genotypes frequency were AA, AG and GG 51.4%, 14.3% and 34.3% in breast cancer patients and 22.9%, 24.2% and 52.9% in the healthy as show in Table (3). This study explain that "A" allele have higher prevalent in the patients with percentage (69.3%) in compared to controls (31.4%).

Table(4) genotype and allele frequency in female breast cancer and healthy groups

		Patients N=70	Healthy N=70	OR (95% C.I)	P-value
	AA	36 (51.4)	16 (22.9)	0.74(0.42-	0.05**
Genotypes	AG	10 (14.3)	17 (24.2)	0.70(0.39- 1.5)	0.47**
	GG	24 (34.3)	37 (52.9)	1	
Allele	A	97 (69.3)	44 (31.4)	0.86(0.5-	0.0001***
type	G	43 (30.7)	96 (68.6)	1.1)	0.0001****

The study appear that AA genotype had a tow-folded or more increase in T1-2 than GG genotype and 47.5 of patients have +ve results to spread of cancer into lymph node . also the study founded that the cancer in about 43.4% of patients were metastasis into other organs . However high frequency 54.8% of female patients in grade 3 as shown in table (5).

Table(5): genotype frequency according to TNM and grade classification.

	AA N (0()	AG	GG	OR(95%)	P-value
C. (C .: .	N (%)	N (%)	N (%)	. ,	
Stage(no.of patients					
T1-T2 (32)	19 (59.4)	5 (15.6)	8 (25)	0.37(0.1-0.47)	0.005**
T3-T4 (38)	21 (55.3)	6 (15.8)	11 (28.9)	1.06(0.5-2.11)	0.18**
LN +ve(40)	19 (47.5)	9 (22.5)	12 (30)	0.95(0.1-0.55)	0.41**
LN -ve (30)	13 (43.3)	7 (23.3)	10 (33.4)	1.33(0.67-2.41)	0.50**
M 0 (24)	9 (37.5)	9 (37.5)	6 (25)	0.94(0.1-0.55)	0.55**
M 1 (46)	20 (43.5)	12 (26.1)	14 (30.4)	3.3(1.2-7.8)	0.006***
Grade					
1 (14)	5 (35.7)	5 (35.7)	4 (28.6)	1.72(0.5-1.01)	0.71**
11 (25)	10 (40)	6 (24)	9 (36)	1.6(1.009-2.49)	0.46**
111 (31)	17 (54.8)	6 (19.4)	8 (25.8)	0.86(0.57-1.10)	0.43**




Figure (3): Gel electrophoresis and PCR product of amplified 179bp of IL-10 gene in breast cancer patients up part represent G allele and down part represent A allele .L : Ladder (100-1517bp) . lane (3,4) represent GG , lane (5,6) represent GA and lane (7) represent AA genotypes .

DISCUSSION

The results revealed that the peak age frequency of (40-49 years) and (50-59 years).(18) recorded that peak age frequency in female patients between age group (40-49) and (50-59) by the Iraqi Cancer Registry. In Baghdad (19) who shows that about 68.2% of the patients were younger than 50 years. (20) they report that mean age of patients with breast cancer at diagnosis was 49 years. Also Alwanet al.,2017 (21) confirmed that about 70.8% of patients presented in the age range between 40-59 years and demonstrated a significant associations with respect to the breast cancer in the family. The higher incidence of breast cancer in this age may related to reproductive factors, or hormonal factors.

Breastfeeding is decreasing the risk of breast cancer among breastfeeding mothers. And the longer women breast feeding they are protected against breast cancer. The researchers find that the risk of breast cancer is decreased by 4.3% for every 12 months of breastfeeding and 7% for each birth. (22) that shows that there is a significant association in Turkish women with breast feeding and decrease risk of breast cancer. Also agree with a study done

by (23) who suggest that breastfeeding for a year or more slightly reduces a woman's overall risk of breast cancer.

(24) who finds that family history of breast cancer indicates a strong association with risk of developing breast cancer. (25) demonstrated that the risk of developing breast cancer is twice as high in women who have an affected first-degree relative than women in the general population. Maruthiet al. (26) observed in their 'study that most breast cancer patients were in aggressive state with high tumor size and the cancer in most patients spread to lymph node and had a metastasis .Alwan ,2016 (27) explain that depending on TNM classification, about 9.8% of female patients presented with stage I disease, and 46% were diagnosed in stages III and IV and more than two-thirds of the patients (65.5%) had positive lymph node involvement. (28) observes that 43% of patients are diagnose in stages III. (29) who prove that (57%) of breast cancer cases are advance stage and grade. (30) confirmed that high frequency of patients were in high stage and grade which reflect the poor health education of the general population and their ignorance regarding the significance of clinical breast examination, breast selfexamination and early medical consultation.

Several single nucleotide polymorphisms (SNPs) have been identified in the IL10promoter (31) . Three functional IL10SNPs have been characterized; these are an adenine (A) to guanine (G) substitution at nucleotide -1082 (rs1800896), a thymine (T) to cytosine (C) substitution at nucleotide -819 (rs1800871), and an A to C substitution at nucleotide -592 (rs1800872). These polymorphisms led to different IL10 expression levels and determined inter-individual differences in IL-10 (32). Moorem(33) mention that Interleukin-10 inhibited T-cell proliferation, and promoted proliferation and (26) observed a significant association of rs1800896 with BC in patients group, where AA genotype showed a two- fold increased risk towards BC and three fold risk towards metastasis. In-silico analyses strengthened observation revealing the alteration in transcription binding site in the IL10 promoter by the mutant allele G.(34) reported that IL10 AA genotype is correlated with a marked increase in breast cancer risk.IL-10-1082 AA genotype was associated with increased BC risk (35). Giordani et al. (36) confirmed a correlation between The -1082 polymorphism with cancer risk in Italy women patients

The seven-fold increased risk of BC seen in patients with low producing genotype (AA) and elevated frequency of low producing AA genotype in patients suggests that predisposing role of this polymorphism in South Indian women (37).In Turkish population observed that haplotypes A frequency is high in BC patients than controls and lower frequency in lymph node negative BC cases (38).. Similarly (39) appeared that *IL-10* "1082G/A heterozygous GA genotypes and A allele were significantly high in asthmatic patientsin contrast homozygous GG genotype and G allele that found at low frequency with asthmatic patients. Chand-Bhayalet al, who revealed that patients with AA genotype more susceptible to cancer than GG genotype (40). This result demonstrate that AA genotype and A allele is risk factor of severity in breast patients,

greater IL-10 protein concentrations are seen in serum of breast cancer patients than in that of healthy individuals and this is associated with poor clinical outcomes, also confirmed that IL-10 producing capability makes individuals susceptible to more aggressive course of the disease (41).

REFERENCE

- 1- Iraqi Cancer Board (2015) Results of the Iraqi Cancer Registry, (2012). Baghdad, Iraqi Cancer Registry Center, Ministry of Health, Iraq.
- 2-Howlader, N.; Altekruse, S.F.; Li ,C.I.; Chen ,V.W. and Clarke ,C.A. (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106: 1-8.
- 3-Coogan, P.F.; White, L.F.; Adler, T.J.; Hathaway, K.M.; Palmer, J.R. and Rosenberg, L. (2009) .Prospective study of urban form and physical activity in the Black Women's Health Study. American journal of epidemiology. 170 (9), 1105.
- 4- Smyth ,M.J.; Cretney ,E.; Kershaw , M.H. and Hayakawa ,Y.(2004) .

 Cytokines in cancer immunity and immunotherapy.

 ImmunolRev.202:275-293.
- 5- Zhang, Sh.; Wang ,Y.; Liu, Ch.; Jiang, J.; Jiang, H.; and Xiao , Z.(2016). Polymorphisms in the interleukin-10 gene and hepatocellular carcinoma: an updated meta-analysis of 12 case-control studies
- Int J ClinExp Med .9(9):17140-17152
- 6-Surhan ,R.K.; Darweesh ,M.F. and Al-Obiadi , A.B.(2017) . IL-10-1082A\G gene polymorphism and production in β -thalassemia major and association with HCV infection
- 7-Khan ,H.; Changkija ,B. and Konwar , R. (2012) . Role of Interleukin-10 in Breast Cancer. Breast Cancer Res Treat. 133(1): 11-21.
- 8-Li, X.; Mai, J.; Virtue, A.; Yin, Y.and Yang, X.F. (2012). IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PLOS ONE. 7 (3): 33628.
- 9- Zhao ,S.; Wu, D.; Wu ,P.; Wang ,Z.H. and Huang J.(2015). Serum IL-10 Predicts Worse Outcome in Cancer Patients: AMeta-Analysis. PLOS One. 2015; 6: 1-15.

- 10- Sung, W.; Huei,L.; Lee ,H.(2013). The role of interleukin-10 in the progression of human papillomavirus associated lung carcinoma. OncoImmunol. 2(9): 1-4.
- 12- Miteva, L.D.; Stanilov, N.S.; Deliysky, T.S. and Stanilova , S.A.(2014). Significance of -1082A/G polymorphism of IL10 gene for progression of colorectal cancer and IL-10 expression. TumourBiol . 35: 12655-12664.
- 13-Hsia, T.C.; Chang ,W.S.; Liang, S.J.; Chen, W.C.; Tsai ,C.H. and Bau, D.T. (2014) .Interleukin-10 (IL-10) promoter genotypes are associated with lung cancer risk in Taiwan males and smokers. Anticancer Res . 34: 7039-7044.
- 14- Pan , F.; Tian ,J.; Pan ,Y.Y. and Zhang ,Y. (2012). Association of IL-10-1082 promoter polymorphism with susceptibility to gastric cancer: evidence from 22 case-control studies. MolBiolRep . 39: 7143-7154.
- 15- You ,Y.; Du, X.; Fan, M.; Wu, B. and Xie ,C. (2015). Association between IL-10 polymorphisms (-1082A/G, -592A/C and -819T/C) and oral cancer risk. Int J ClinExpMed . 8: 13187-13194.
- 16-Singletary, S.E.; Allred, C.; Ashley, P.; Bassett, L.W.; Berry, D.; Bland, K.I.; Borgen, P.I. and Hayes, D.F. (2002). Revision of the American Joint Committee on Cancer staging system for breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 20(17):3628-3636.
- 17-Ali, A. A and Settin ,A. A. (2013) . Molecular genetic analysis of polymorphisms pertaining to the susceptibility to chronic asthma in Egyptian patients. The Journal of Basic and Applied Zoology 66, 188-194.
- 18- Iraqi Cancer Registry , (2009). Iraqi Cancer Board. Ministry of Health
- 19- Mayada, I.Y. (2013). Esterogen and Progesterone Receptors (ER and PR) status of Breast Cancer Cases in Kurdistan and Their Correlation with Pathologic Prognostic Variables. Medical Journal of Babylon;10(1):75-84.
- 20-Rambau, P.F.; Chalya, PL.; Manyama, M.M. and Kahima, J.K. (2011).Pathological features of breast cancer seen in Northwestern Tanzania: a nine years retrospective study. BMC Research Notes4, 214
- 21-Alwan N.S.; Tawfeeq, F.N.; Muallah,M.H.; Sattar, S.A. and Saleh,W.S. (2017). The Stage of Breast Cancer at the Time of Diagnosis: Correlation with the Clinic pathological Findings among Iraqi Patients. J. of Neoplasm. 2(3):1-11
- 22- Kuru, B.; Ozaslan, C.; Ozdemir, P.; Dinç, S.; Camlibel , M. and Alagol, H.(2002). Risk factors for breast cancer in Turkish women with early pregnancies and long lasting lactation-a case control study. ActaOncol, 41:556-561.
- 23 Faupel-Badger , J.M.; Arcaro, K.F.; Balkam , J.J. (2013) . Postpartum remodeling, lactation, and breast cancer risk : summary of a National Cancer Institute-sponsored workshop. J. Natl. Cancer Inst. 105(3):166-174.
- 24- Darweesh, A. (2009). Risk factors of breast cancer among Palestinian women in North West bank, An-Najah National University, Nablus, Palestine.
- 25- Schwartz, GF.; Hughes, KS. and Lynch, H.T. (2008). Proceedings of the international consensus conference on breast cancer risk, genetics, and risk management. Cancer. 113(10):2627-37.
- 26- Maruthi, G.; Ramachander, V.; komaravalli, P.; Sureka.K. andJahan, P.(2017). Association of Il10 Gene Polymorphisms (Rs 1800896, Rs1800872) in Breast Cancer Patients. International Journal of Medical Science and Clinical Inventions 4(6): 3050-3061
- 27- Alwan , N.S.(2016) .Breast Cancer Among Iraqi Women: Preliminary Findings From a Regional Comparative Breast Cancer Research Project. Journal of Global Oncology . 2 (5):255-259.
- 28-Al-hamadawi, HA., Al-Kashwan, TA., Al-Janabi, AA., Al-bideri, AW., Allebban, ZS., Jaber, AH., and Al-Ghazali, HR., (2015). Interaction between Altered P53 and PTEN Inactivation has a biological predictive implication in assessment of aggressive breast cancer. Int.J.Curr.Microbiol.App.Sci4(5): 910-922.
- 29-Stark, A., Kapke, A., Schultz, D., Brown, R., Linden, M., Raju, U. (2008). Advanced stages and poorly differentiated grade areassociated with an increased risk of HER2/neu positive breastcancer only in white women: findings from a prospective cohort study of African-American and white- Americanwomen. Breast Cancer Res Treat; 107:405–414.
- 30-Etzioni, R.; Urban, N.; Ramsey, S.; McIntosh, S.; Reid, B.; Radich, J.; Anderson, G. and Hartwell, L. (2003). The case for early detection. Nature Reviews Cancer3(4): 243.

- 31-Howell ,M.W. (2000) . Interleukin-10 Gene Polymorphisms and Cancer. Madame Curie Bioscience Database. Landes Bioscience. 2000; 8:2013-2015.
- 32-Sheikhpour, R. and Mohiti, J. (2014) . The effect of progesterone on p53 in T47D cell line. Urmia J Med Sci . 25 (10), 954-960.
- 33- Moorem, K.W.; De- Waal, M.R.; Coffman, R.L. and O'Garra A. (2001) . Interleukin–10 and the interleukin–10 receptor. Annu Rev Immunol. 19:683–765.
- 34- Giordani ,L. (2003). Association of Breast Cancer and polymorphisms of Interleukin-10 and Tumor Necrosis Factor- α Genes, Clinical Chemistry 49(10):1-6.
- 35- Vinod, C.; Jyothy,A.; kumar, M.; Raman, R.R.; Nallari, P.andVenkateshwari, A.(2015).A Common SNP of IL-10 (-1082A/G) is Associated With Increased Risk of Premenopausal Breast Cancer in South Indian Women. India Iran J Cancer Preven. 8(4): 3434.
- 36- gonullu,G.; Basturk,B.; Vrensel,T.; Burboros , O.; Ayse,G.; Manvoglu, O.(2007) .Association of breast cancer and cytokine gene polymorphisms in Turkish women .Saudi med j . 28(11);1728-1733.
- 37-InduKohaarPratibha Tiwari Rakesh Kumar Vilas NasareNisha Thakur Bhudev C. Das Mausumi Bharadwaj.2009.Association of single

- nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population"Breast Cancer Res Treat (2009) 114:347–355.
- 38-Korobeinikova, E.; Myrzaliyeva, D.; Ugenskiene, R.; Jurgita .; and Juozaityte, E.(2015). The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients .15: 0234-8.
- 39Kadhem, E.K. and Darweesh, M.F. (2017) . Association of IL-10G/A gene polymorphism with its serum levels in asthma patients . Biochem. Cell. Arch. 17(2): 709-713
- 40 -Chand-Bhayal, A.; Krishnaveni, D.; Pandu-Ranga-Rao, K.; Prabhakar, B.;Nallari,P. and Venkateshwar, A. (2012). Association of Interleukin-10 Promoter Polymorphism (-1082 G/A) and Gastric Cancer in Andhra Pradesh Population of South India. Iran J. Cancer Prev.; 3:117-123.
- 41-Roba ,M.; Talaat, A.; Abdel-Aziz,M.; El-Maadawy, E. and abdel-Bary,N.(2013).Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL)". (9):1-6.